The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition (CPPD) disease were developed to standardize diagnosis and facilitate research. These criteria consist of weighted points assigned to different clinical features, associated metabolic disorders, and results of laboratory and imaging tests. A score of over 56 points indicates a high probability of CPPD disease.
Here's a breakdown of the criteria:
- Entry Criterion: Ever having experienced at least one episode of joint pain, swelling, or stiffness.
- Clinical Features:
- Joint Involvement: Presence of specific joints affected, like the knee, wrist, or shoulder.
- Acute Articular Inflammation: Episodes of sudden, severe joint pain and swelling.
- Chondrocalcinosis: Calcification within cartilage seen on imaging.
- Joint Deformity: Abnormal joint shape due to CPPD.
- Pseudogout: Synovial fluid analysis reveals calcium pyrophosphate crystals.
- Associated Metabolic Disorders: Presence of conditions like hypothyroidism, hyperparathyroidism, or diabetes.
- Laboratory and Imaging Tests:
- Blood Tests: Elevated levels of inflammatory markers like ESR or CRP.
- Imaging: X-ray, ultrasound, or MRI showing chondrocalcinosis.
These criteria are used to assess the likelihood of CPPD disease, and their application helps standardize the diagnostic process and provide a framework for future research.
